Biotechnology

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

A new multi-target deal combines cutting-edge platforms to create next-gen cancer drugs, aiming to improve precision and patient outcomes.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

UBC's strategic buyout of AI-specialist Evidinno signals a major shift in evidence generation, promising faster, smarter data solutions for biopharma.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

The newly merged Medispend aims to dominate the compliance software market with an expanded suite, deep financial backing, and a string of strategic buys.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

A new AI-powered simulation engine promises to replace strategic gut feelings with statistical certainty, helping companies navigate high-stakes decisions.

Bio-Rad's leadership will meet investors at the J.P. Morgan conference, facing questions on strategy and growth in a competitive, tech-driven market.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.